DUBLIN--(BUSINESS WIRE)--The "Retinal Vein Occlusion - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Retinal Vein Occlusion - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 3, 11, 1 and 1 respectively.
Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Mentioned
- Acucela Inc
- Addmedica SAS
- Annexin Pharmaceuticals AB
- Celon Pharma SA
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Clearside BioMedical Inc
- EyeGate Pharmaceuticals Inc
- Eyevensys SAS
- Formycon AG
- Gene Signal International SA
- Graybug Vision Inc
- Lupin Ltd
- Mabion SA
- Novartis AG
- Ocular Therapeutix Inc
- Ohr Pharmaceutical Inc
- Profarma
- Regeneron Pharmaceuticals Inc
- SciFluor Life Sciences LLC
- ThromboGenics NV
For more information about this report visit https://www.researchandmarkets.com/research/qtchcz/retinal_vein?w=4
